PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC.

ABSTRACT: Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy remains a clinical challenge. This study evaluated the functional binding of PD-1 ligands in 29 HNSCC patients and compared it to the standard PD-L1 Combined Positive Score (CPS). The assessment of PD-1 ligands' functionality advances the current ability to predict the response of HNSCC patients to anti-PD-1 therapy.

SUBMITTER: Kaufman B 

PROVIDER: S-EPMC11148182 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature